Generation of aerosolized drugs.
The expanding use of inhalation therapy has placed demands on current aerosol generation systems that are difficult to meet with current inhalers.  The desire to deliver novel drug entities such as proteins and peptides, as well as complex formulations including liposomes and microspheres, requires delivery systems of improved efficiency that will target the lung in a reproducible manner.  These efforts have also been spurred by the phase out of chlorofluorocarbons (CFCs) and this has included a directed search for alternative propellants.  Consequently, a variety of new aerosol devices and methods of generating aerosols are being studied. This includes the use of freon replacement propellants, dry powder generation systems, aqueous unit spray systems and microprocessor controlled technologies.  Each approach has advantages and disadvantages depending upon each principle of action and set of design variables.  In addition, specific drugs may be better suited for one type of inhaler device vs. another.  The extent to which aerosol generation systems achieve their goals is discussed together with a summary of selected papers presented at the recent International Congress of Aerosols in Medicine.
Toxicology Research Laboratories, Lilly Research Laboratories, Greenfield, IN  46140.
R K
RK
Wolff
R W
RW
Niven
D000280:Administration, Inhalation; D000335:Aerosol Propellants; D000336:Aerosols / Q000008:administration & dosage*; D004867:Equipment Design; D006801:Humans; D009330:Nebulizers and Vaporizers / Q000639:trends; D010316:Particle Size